Page 5 - Cost Effectiveness News Today

Experts discuss the landscape of treatment options for Duchenne muscular dystrophy, examine the benefits and risks of gene therapy and conventional steroid treatments, and emphasize the need for early intervention and comprehensive care.

Fe electrocoagulation technology was proposed for roxarsone (3-nitro-4-hydroxyphenyl-arsonic acid, ROX) removal from water. The effects of current density (CD) and initial pH on ROX removal and operating costs were evaluated using batch tests. Results showed a high total arsenic (TAs) removal efficiency (≥ 99.5 %) at 40 min (CD 1.75–8.77 A/m2, pH 4.6–8.6). Sludge treatment cost accounted for the highest proportion of total operating costs. High concentrations of HCO3− and humic acid had ...

SCG presents solutions aimed at enhancing business value and reducing costs for hotel groups, banquet halls, office buildings, hospitals, educational institutions, and industrial factories. These solutions cover various business needs, ensuring

Emma Ciafaloni, MD, FAAN, explores the groundbreaking approval of onasemnogene abeparvovec-xioi for spinal muscular atrophy and its impact on the treatment paradigm for this rare disease.

Ryan Haumschild, PharmD, MS, MBA, and Mary Pak, MD, FACP, consider FDA-approved gene therapies for hemophilia, spinal muscular atrophy, and Duchenne muscular dystrophy, exploring their genetic foundations, the FDA approval process, and considerations for therapeutic value and cost.

Intensive surveillance after resection on patients with colorectal cancer (CRC) was less cost-effective in stage I but most cost-effective in stage II and III disease.

Emma Ciafaloni, MD, FAAN, describes the key differences among viral vectors used in gene therapy, highlighting their applications and strengths in targeting specific diseases.

Experts delve into the fundamentals of gene therapy, covering in vivo and ex vivo methods, and explore cellular function targets for effective treatment of a disease.

Jessica Nance, MD, MS, discusses maximizing gene therapy efficiency by selecting vectors for gene size, tissue targeting, and low exposure, and focusing on precise promoters for expression.

The TOPS device, for lumbar facet arthroplasty, is more cost-effective compared to a transforaminal lumbar interbody fusion when addressing degenerative spondyl